Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his ...

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Researchers are exploring new treatment options for chronic myeloid leukemia (CML ... Dasatinib is another TKI targeted therapy drug. Clinical trials are studies comparing new treatments to ...

TC BioPharm (TCBP) announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

It's important to note that clinical trials for children are different than trials for adults. Here is what you should know.

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

PLC (NASDAQ: TCBP) shares lost some ground Monday, as the Edinburgh-based clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Blinatumomab, which recently completed clinical trials and has won approval from the FDA, is a drug designed to treat acute lymphoblastic leukemia, one of the most common types of blood and bone ...

Cohort B recruitment continues at multiple clinical sites across the United Kingdom EDINBURGH, Scotland, Feb. 10, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") ...